Elevance Health (NYSE:ELV) Issues FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) issued an update on its FY 2026 earnings guidance on Saturday. The company provided earnings per share (EPS) guidance of 27.000- for the period, compared to the consensus EPS estimate of 27.160. The company issued revenue guidance of -.

Elevance Health Trading Down 0.9%

Shares of NYSE:ELV opened at $410.71 on Friday. Elevance Health has a 52-week low of $274.84 and a 52-week high of $436.24. The company has a market capitalization of $89.07 billion, a P/E ratio of 18.25, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. The company has a 50-day simple moving average of $397.09 and a 200 day simple moving average of $369.87. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm had revenue of $49.83 billion for the quarter, compared to the consensus estimate of $48.88 billion. During the same quarter in the previous year, the business earned $8.84 earnings per share. The business’s revenue was up .8% compared to the same quarter last year. Sell-side analysts forecast that Elevance Health will post 27.18 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is currently 30.58%.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Morgan Stanley upped their price objective on shares of Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a report on Thursday, June 4th. Robert W. Baird lifted their target price on shares of Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. JPMorgan Chase & Co. upped their price target on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Mizuho raised their price objective on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, Raymond James Financial set a $450.00 price objective on Elevance Health in a report on Tuesday, July 7th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $440.90.

Elevance Health Company Profile

Elevance Health, Inc is a health benefits and services company that provides health insurance, care management and related healthcare solutions in the United States. The company serves individuals, employers and government-sponsored programs through a portfolio that includes commercial health plans, Medicare Advantage and other Medicare products, Medicaid plans, and specialty coverage.

Elevance Health operates a portfolio of Blue Cross Blue Shield-affiliated health plans and offers products such as medical, pharmacy, dental and vision benefits.